Crossmark

WEE1 kinase inhibition to overcome acquired resistance to targeted therapies in colorectal cancer

Crossref DOI link: https://doi.org/10.1038/s44321-026-00434-4

Published Online: 2026-05-19

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Buzo, Kristi

Bizzozero, Laura

Lentini, Marilena

Opattova, Alena

Hernández-Suárez, Beatriz

Torres, Michael

Chiabotto, Giulia

Nisticò, Clelia https://orcid.org/0000-0002-0787-9527
De Lazzari, Giada https://orcid.org/0000-0002-5217-8201
R Zanella, Eugenia

Grasso, Gaia

Mariella, Elisa

Durinikova, Erika

Linnebacher, Michael https://orcid.org/0000-0001-8054-1402
Sartore-Bianchi, Andrea

Siena, Salvatore

Trusolino, Livio https://orcid.org/0000-0002-6379-3365
Bardelli, Alberto

Arena, Sabrina https://orcid.org/0000-0002-1318-2494
Funding

Funding for this research was provided by:

BRIDGE (2022-ID 27321)

Ministero dell'Istruzione, dell'Università e della Ricerca (2022LSFKWE)

Ministero dell'Istruzione, dell'Università e della Ricerca (2023-2027 14586 DIORAMA)

Ministero dell'Istruzione, dell'Università e della Ricerca (PNC0000001)

Ministero dell'Istruzione, dell'Università e della Ricerca (2023-2027 14586)

EC | NextGenerationEU (P2022E3BTH)

EC | Horizon Europe | Excellent Science | HORIZON EUROPE European Research Council (101020342)

Fondazione AIRC per la ricerca sul cancro ETS (21091)

Fondazione AIRC per la ricerca sul cancro ETS (28922)

Fondazione AIRC per la ricerca sul cancro ETS (29286)

Fondazione AIRC per la ricerca sul cancro ETS (27321)

Ministero della Salute (FPRC 5x1000 Ministero della Salute 2022 CARESS)

Ministero della Salute (Ricerca Corrente 2026 to the Candiolo Cancer Institute,FPO-IRCCS)

Ministero della Salute (2021 EmaGen)

Ministero della Salute (2022 CARESS)

Ministero della Salute (Ricerca Finalizata 2021,ID RF-2021-12372851)

EC | Horizon 2020 Framework Programme (754923 COLOSSUS)
License Information

Text and Data Mining valid from 2026-05-19

Version of Record valid from 2026-05-19
More Information

Article History

Received: 30 September 2025

Revised: 9 April 2026

Accepted: 17 April 2026

First Online: 19 May 2026

Disclosure and competing interests statement

: S. Arena (SA) reports personal fees from MSD Italia and a patent (Italian patent application No. 102022000007535) outside the submitted work. A. Bardelli (AB) declares the following competing financial interests: receipt of grants/research supports from Neophore; stock shareholder: Neophore, Kither Biotech; member of the SAB of Neophore. Livio Trusolino (LT) has received research grants from Menarini, Merck KGaA, Merus, Pfizer, Servier and Symphogen.

Document is current

Any future updates will be listed below